Nanolive banks $20 million in Series C1 round

Nanolive’s cutting edge label-free microscope devices and state-of-the-art digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy.

Being able to screen thousands of living cells in 3D without damaging them promises to radically advance how scientists study living cells. But the quantitative analytical suite Nanolive offers is a complete game-changer. Combining sub-cellular resolution with unique AI-assisted digital assays allows researchers and scientists to quantitatively study complex cell-drug perturbation dynamics and cell-cell interactions (for instance, T cell and target cell interactions). This approach will revolutionize the cell-based assay phase of the drug discovery workflow and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.

Today, Nanolive announced the first closing of its Series C investment round, raising $20 million. The round saw the lead participation of a US-based and NASDAQ listed life science investor and Taiwania Capital, Taiwan’s leading life sciences investment firm focusing on early to late-stage companies. Existing investors, including Swisscom Ventures, joined other undisclosed partners in the round. Locust Walk, a leading life sciences transaction advisory firm, served as transaction advisor to Nanolive SA.

 “Life Sciences are undergoing a fundamental transformation, and Nanolive is at the heart of it,” says Yann Cotte, Nanolive’s CEO and Co-Founder. “We are honoured to receive an investment from such an impressive group of investors who are excited to support us in our goal to transform the discovery and development of therapeutics. With this fundraising, we believe Nanolive is well-positioned to drive significant growth of our Digital Assay solutions and is at the leading edge of this global bioeconomy gold rush. We are selling the best picks and shovels for live-cell solutions.”

“We are thrilled to be part of a Swiss-based innovative company that will revolutionize the drug discovery process,” said Michael L. Huang, Managing Partner of Taiwania Capital. “With this funding, Nanolive is well-positioned to provide crucial tools and solutions to pharmaceutical and biotech companies and research institutes for developing better therapies that would save millions of patient lives”.

(Press release/RAN)